explore -WSS

explore

author：knowledge 2025-09-27 09:44:33 - browse：78718

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Why ADHD is under

explore

WSS

Caregivers of transplant patients call for more support, training

Biden launches a new push to limit health care costs

New Medicare drug pricing powers could soon be upended in court

How I ended up pumping milk in a bathroom stall at JPM 2024

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Living with Fabry disease, a condition that causes chronic pain

hotspot

explore

leisure time

Activists slam private health insurers over coverage restrictions

Generative AI mines health records to identify patients’ social needs

How one medical school became remarkably diverse

Designating disabled people as health disparity population is crucial

As demand for Covid shots wanes, Moderna seeks its next success

Lecanemab for Alzheimer's is coming. Is the health system ready?

Cancer drug shortages should be causing more outrage

Generative AI mines health records to identify patients’ social needs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Three issues to watch in global health in 2024

entertainment

Generative AI mines health records to identify patients’ social needs

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Lecanemab for Alzheimer's is coming. Is the health system ready?

N.Y. state detects polio case, first in the U.S. since 2013

Idaho abortion case may prompt more restrictions in other states

focus

knowledge

explore

hotspot